financial statements 38. relateD Parties transactions between the company and its subsidiaries have been eliminated on consolidation and are not disclosed in this note.
transactions between the group and its associates and other related parties are disclosed below.
trading transactions: During the year, group companies entered into the following transactions with related parties: Darhold Limited: is a related party of the group because it is considered one of the major shareholders of Hikma Pharmaceuticals Plc with an ownership percentage of 28.9% at the end of 2013 2012: 29.0%.
further details on the relationship between mr. samih Darwazah, mr. said Darwazah, mr. mazen Darwazah and mr. ali al-Husry, and Darhold limited are given in the Directors report.
other than dividends as paid to all shareholders, there were no transactions between the group and Darhold limited in the year.
Capital Bank Jordan: is a related party of the group because two Hikma Pharmaceuticals Plc Board members are also Board members ofcapital Bank Jordan.
total cash balances at capital Bank Jordan were $17.2 million 31 December 2012: $3.0 million.
facilities granted bycapital Bank to the group amounted to $4.7 million 31 December 2012: $nil.
interest expense income is within market rate.
Arab Bank: During the year, one member of Hikma Pharmaceuticals Plc senior management became a board member of arab Bank Plc.
total cash balances at arab Bank were $51.5 million 31 December 2012: $75.7 million.
facilities granted by arab Bank to the group amounted to$169.4 million 31 December 2012: $187.1 million.
Jordan International Insurance Company: is a related party of the group because one Board member of the company is also a Board member at Hikma Pharmaceuticals Plc.
total insurance premiums paid by the group to Jordan international insurance company during the year were $0.2 million 2012: $3.4 million.
the groups insurance expense for Jordan international insurance company contracts in the year 2013 was $0.2 million 2012: $2.8 million.
the amounts due to Jordan international insurance company at the year end were $0.1 million 2012: Due to$0.2 million.
Mr. Yousef Abd Ali: is a related party of the group because he holds a non-controlling interest in Hikma lebanon of 33%, the amount owed frommr.
yousef by the group as at 31 December 2013 was $nil due to in 2012: $0.2 million.
Labatec Pharma: is a related party of the group because it is owned by mr. samih Darwazah.
During 2013, the group total sales to labatec Pharma amounted to $0.4 million 2012: $0.3 million and the group total purchases from labatec Pharma amounted to $nil 2012: $1.2 million.
at 31 December 2013, the amount owed from labatec Pharma to the group was $nil 2012: owed from $0.2 million.
King and Spalding: is a related party of the group because a partner of the firm is a Board member and the company secretary of West-Ward.
king and spalding is an outside legal counsel firm that handles general legal matters for West-Ward.
During 2013, fees of $nil 2012: $0.1 million were paid for legal services provided.
Jordan Resources & Investments Company: is a related party of the group because three Board members of the group are shareholders inthefirm.
During 2013, fees of $0.2 million 2012: $0.2 million were paid for training services provided.
American University of Beirut: is a related party of the group because one Board member of the group is also a trustee of the university.
During 2013, fees of $0.1 million 2012: $0.1 million were paid for training services provided.
at 31 December 2013, the amount owed toamerican university of Beirut from the group amounted to $0.1 million 2012: owed to $nil.
HikmaCure: During 2013, the group signed a 50:50 joint venture Jv agreement with miDroc Pharmaceuticals limited.
the Jv is called Hikmacure.
Hikma and miDroc will invest in Hikmacure in equal proportions and have committed to provide up to $22 million each in cash, ofwhich $3 million has been paid during the year.
Unimark: the group held a non-controlling interest of 23.1% in the indian company unimark remedies limited unimark, at 31 December 2013 2012: 23.1%.
During 2013, the group amount of $3 million was in relation to a product development agreement.
Haosun: the group held a non-controlling interest of 30.1% in Hubei Haosun Pharmaceutical co. ltd Haosun at 31 December 2013 2012: 30.1%.
During 2013, the total purchases from Haosun was $0.2 million 2012: $0.3 million.
